Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Guoda Lian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6116-6173; OpenAlex author ID A5002028873. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 20

  1. Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Co-author DOI 10.1039/d5nr90172c↗
  2. Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer. Last author DOI 10.1002/jev2.12484↗
  3. Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02880-8↗
  4. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Co-author DOI 10.1016/j.phrs.2022.106555↗
  5. Development and validation of a radiomics model of magnetic resonance for predicting liver metastasis in resectable pancreatic ductal adenocarcinoma patients. Last author DOI 10.1186/s13014-023-02273-w↗
  6. Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia… Co-author DOI 10.1039/d2bm01039a↗
  7. A LETM2-Regulated PI3K-Akt Signaling Axis Reveals a Prognostic and Therapeutic Target in Pancreatic Cancer. Last author DOI 10.3390/cancers14194722↗
  8. GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network. Co-author DOI 10.7150/jca.72161↗
  9. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.bcp.2020.114085↗
  10. Peripheral blood monocytes predict clinical prognosis and support tumor invasiveness through NF-κB-dependent upregulation of Snail in pancreatic cancer. Co-author DOI 10.21037/tcr-21-980↗
  11. Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer. Co-author DOI 10.3389/fgene.2021.632803↗
  12. Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. Co-author DOI 10.1002/cam4.2930↗
  13. Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Co-author DOI 10.1039/c9nr04976b↗
  14. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8. First author DOI 10.1002/cam4.1824↗
  15. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Co-author DOI 10.1002/ijc.31248↗
  16. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Co-author DOI 10.7150/thno.24281↗
  17. New developments in the early diagnosis of pancreatic cancer. Co-author DOI 10.1080/17474124.2017.1271323↗
  18. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Co-author DOI 10.1111/cas.13267↗
  19. Pancreatic Cancer Epidemiology, Detection, and Management. Co-author DOI 10.1155/2016/8962321↗
  20. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy. Co-author DOI 10.1166/jbn.2016.2269↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaihong Huang · 20 shared papers, 2016–2025 · strength 2.51
  2. Yaqing Li · 16 shared papers, 2016–2025 · strength 2.11
  3. Shaojie Chen · 13 shared papers, 2016–2024 · strength 1.59
  4. Jinmao Zou · 9 shared papers, 2020–2025 · strength 1.46
  5. Yinting Chen · 13 shared papers, 2016–2025 · strength 1.35
  6. Shangxiang Chen · 8 shared papers, 2020–2025 · strength 1.18
  7. Linjuan Zeng · 9 shared papers, 2016–2025 · strength 0.85
  8. Kege Yang · 8 shared papers, 2016–2024 · strength 0.83
  9. Jiajia Li · 7 shared papers, 2016–2024 · strength 0.83
  10. Shurui Zhou · 5 shared papers, 2022–2024 · strength 0.80
  11. Yue Zhao · 3 shared papers, 2022–2024 · strength 0.54
  12. Ziyi Zhong · 3 shared papers, 2022–2024 · strength 0.53
  13. Hanming Yao · 3 shared papers, 2022–2024 · strength 0.50
  14. Shaojie Chen · 3 shared papers, 2020–2025 · strength 0.48
  15. Jiajia Li · 3 shared papers, 2017–2024 · strength 0.41
  16. Jiajia Li · 3 shared papers, 2016–2025 · strength 0.40
  17. Yunlong Li · 2 shared papers, 2022–2024 · strength 0.34
  18. Yuzhou Huang · 2 shared papers, 2022–2023 · strength 0.32
  19. Qiubo Zhang · 4 shared papers, 2016–2020 · strength 0.30
  20. Fengjiao Li · 2 shared papers, 2022–2023 · strength 0.29
  21. Chumei Huang · 4 shared papers, 2017–2018 · strength 0.29
  22. Ying Tan · 2 shared papers, 2020–2021 · strength 0.23
  23. Yuzhou Huang · 1 shared paper, 2024 · strength 0.20
  24. Yanji Luo · 1 shared paper, 2023 · strength 0.18
  25. Ming Gao · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.